(Q42382560)

English

Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet

scientific article published on 6 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 October 2017

Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet (English)

1 reference

Europe PubMed Central

28 October 2017

0 references

glucose monitoring

1 reference

based on heuristic

inferred from title

author name string

R Nishimura

1

1 reference

Europe PubMed Central

28 October 2017

H Omiya

2

1 reference

Europe PubMed Central

28 October 2017

K Sugio

3

1 reference

Europe PubMed Central

28 October 2017

M Ubukata

4

1 reference

Europe PubMed Central

28 October 2017

S Sakai

5

1 reference

Europe PubMed Central

28 October 2017

Y Samukawa

6

1 reference

Europe PubMed Central

28 October 2017

publication date

6 December 2015

1 reference

Europe PubMed Central

28 October 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

28 October 2017

18

1 reference

Europe PubMed Central

28 October 2017

7

1 reference

Europe PubMed Central

28 October 2017

702-706

1 reference

Europe PubMed Central

28 October 2017

SGLT2 Inhibitors May Predispose to Ketoacidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossov

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Luseogliflozin for the treatment of type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

28 May 2018

Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

16 August 2018

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5066655

16 August 2018

Luseogliflozin: First Global Approval

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12611

21 January 2018

Identifiers

10.1111/DOM.12611

1 reference

Europe PubMed Central

28 October 2017

1 reference

Europe PubMed Central

28 October 2017

1 reference

Europe PubMed Central

28 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42382560&oldid=1943177259"